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Abstract.
Background: Soluble oligomeric amyloid- (A), rather than A plaques, seems to be the culprit in Alzheimer’s disease
(AD). Accordingly, a new concept vaccine of small cyclic peptide conjugates, selectively targeting oligomeric A, has been
developed.
Objective: Study the therapeutic potential of this new vaccine in a mouse model for AD.
Methods: J20 mice, overexpressing human amyloid precursor protein, were validated for an AD-like phenotype. Then, J20
mice were vaccinated at 2, 3, and 4 months of age and AD phenotype was evaluated at 6, 9, and 12 months of age; or at 9, 10,
and 11 months with evaluation at 12 months. Effects on A pathology were studied by plaque load (immunohistochemistry;
6E10) and antibody titers against A (ELISA). AD behavioral phenotype was evaluated by performance in a battery of
cognitive tests.
Results: J20 mice displayed age-related A plaque development and an AD-like behavioral phenotype. A consistent antibody
response to the cyclic peptides was, however, not extended to A, leaving plaque load unaffected. Nevertheless, immunization
at young ages prevented working- and short-term spatial memory loss, but deteriorated long-term spatial learning and memory,
at 12 months of age. Immunization at later ages did not affect any measured parameter.
Conclusion: J20 mice provide a relevant model for AD to study potential anti-A treatment. Early vaccination prevented
short-term memory loss at later ages, but deteriorated long-term spatial memory, however without affecting A pathology.
Later vaccination had no effects, but optimal timing may require further investigation.
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INTRODUCTION
Alzheimer’s disease (AD) has been described for
the first time in 1906 by Dr. Alois Alzheimer as a
peculiar disease. Since then, AD has become the most
prevalent neurodegenerative disease of adult-onset,
causing up to 70% of all dementia worldwide [1].
Patients suffering from AD show progressive loss of
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cognitive functions resulting from severe neurode-
generation of the brain. Age is the major risk factor
for AD, and as yet there is no effective treatment.
AD is characterized by an accumulation of
amyloid- (A) and tau proteins, leading to extra-
cellular A plaques and intracellular neurofibrillary
tau-tangles [2]. The plaques consist of A, generated
from the amyloid- protein precursor (APP) [3].
These proteins can undergo conformational change,
subsequently aggregating into fibrils and ultimately
deposited into plaques. It was until recently that
the neuronal dysfunction in AD was attributed to
toxic effects of these A plaques [4]. However, the
correlation between plaques and cognitive function
appears to be poor, and evidence is accumulating
that the oligomeric soluble misfolded A, rather
than the fibrillary plaques, are the culprit in AD
[5]. Plaque formation then may even be regarded
as a protective mechanism of the body to stabilize
these toxic peptides [6]. Accordingly, attention has
shifted to the oligomeric A as potential therapeutic
target. Attempts have been undertaken to decrease
neurodegeneration caused by A peptides through
immunization against A [7, 8]. In this regard,
active immunization would be preferred above pas-
sive immunization, because a long-term effect could
be established with few injections, and the patient’s
own immune system is programmed to remove the
misfolded A peptides. Despite the logic of this
approach, there are no major breakthroughs yet. In
2002, the first active AD vaccine (AN1792), contain-
ing the full-length A1–42 peptide, was developed.
This vaccine went through a phase IIa clinical trial
and showed beneficial effects, including less cog-
nitive decline, but had to be discontinued because
6% of the subjects developed meningoencephalitis
[9–11]. The vaccine could have evoked an immune
response against the pathological misfolded A, but
also against the physiological proper linear peptide.
Although the physiological role of A has not yet
been clearly revealed, recent papers suggest to specif-
ically target the proven toxic forms of A [7, 8].
Accordingly, Hoogerhout and coworkers [12] devel-
oped a concept vaccine that was selectively directed
to the misfolded oligomeric A, by mimicking the
bend in the molecular structure with small cyclic
peptides. They showed that immunization with these
small cyclic peptides conjugated to tetanus toxoid
(TTd) induces antibodies to A in Balb/c mice. The
antibodies were highly specific for misfolded A, as
they did not recognize the homologous unmodified
linear peptide nor APP [12]. Moreover, the anti-
bodies cross-reacted in vitro with amyloid plaques
and oligomeric and fibrillar A1–42 in mouse and
human brain tissue. In a Nucleus Basalis of Meyn-
ert lesion model [13], C57BL/6 mice that were
immunized with these small cyclic peptides showed
significantly less cholinergic fiber loss upon stimula-
tion with oligomeric A than mock-immunized mice.
Although the effect was rather small, the results were
considered highly promising for further research. The
next step would be to study the effects of this vacci-
nation procedure in an appropriate AD mouse model.
Transgenic J20 mice overexpress the human APP
[14], resulting in spontaneous development of A
plaques and cognitive deficits, starting from the age
of 6 months [15]. The aim of the present study is
to investigate whether active immunization at young
age prevents or delays the development of cognitive
decline and plaque load in J20 mice at later ages.
Secondly, effects of active immunization at later ages,




Experiments were performed using 220 male J20
mice that expresses the mutant form of the human
amyloid protein precursor (APP) bearing both the
Swedish (K670N/M671L) and the Indiana (V717F)
mutations, under control of the human platelet
derived growth factor B polypeptide promoter. This
strain, originally obtained from Jackson (USA), is
bred in our own facility (Groningen, The Nether-
lands). In addition, 25 male wild type littermate mice
from the J20 breeding colony were included. At the
age of 7 weeks, all mice were housed individually
in macrolon type I L cages (length 30,0 cm, width
12 cm, height 13 cm; Bayer, Germany) with sawdust
as bedding, a cardboard tunnel as cage enrichment
and shredded cardboard as nesting material. Hous-
ing occurred in climate rooms (temperature 22 ± 1◦C,
humidity 50 ± 10% and a reversed light/dark sched-
ule of 12 h light (±50 lux) and 12 h dark, normal
tap water and food (standard rodent chow: RMHB/
2180, Arie Block BV, Woerden, NL) ad libitum. All
mice were weighted every 2 weeks and checked daily
for health/activity/food/water and abnormal behav-
ior. Cages were cleaned once every two weeks. All
procedures were in accordance with the regulation
of the ethical committee for the use of experimen-
tal animals of the University of Groningen, The
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Fig. 1. Experimental outline of the study. OF, Open Field; NOR, Novel Object Recognition; NLR, Novel Location Recognition; SA,
Spontaneous Alternation; V, active vaccine; M, mock vaccine; S, sacrifice #: group 10 has been added later to verify suitability of behavioral
tests for 12-month-old mice.
Netherlands. Mice were genotyped at inclusion and at
sacrifice; only mice that display the right phenotype
at both occasions were included in the analyses.
Experimental outline
Mice at the age of ∼7 weeks were randomized
into groups 1–9 (dependent on genotype) presented
in Fig. 1 (35 mice per vaccination group; 25 mice
per mock treated group; 15 non-treated J20; 15 wild
type littermates). The mice were habituated to the cli-
mate room and housing conditions for at least seven
days before receiving the first round of immunization.
Mice were immunized either before plaque devel-
opment, or after established plaque formation [14],
while control mice received mock vaccine. According
to the schedule in Fig. 1, mice that were vacci-
nated/mock treated early, received 3 vaccine/mock
injections at 2, 3, and 4 months of age (prevention
groups 1–5) and were tested at 6, 9, and 12 months
of age, while delayed vaccination/mock treated mice
received injections at 9, 10, and 11 months of age
(regression groups 6–7) and were tested at 12 months
of age. Non-treated 6-month-old J20 and littermate
wild type mice were included to verify a strain-related
behavioral phenotype. At a later phase, a 12-month-
old non-treated wild type group (littermates of the
included J20 mice) was added to confirm effective-
ness of our behavioral tests for mice this age. Since
the latter group was added at the age of around 10
months and hence did not follow the same proce-
dures as the other mice, this group was not used for
statistical comparison.
Two weeks after the last injection of vaccine
or mock, serum samples were collected by tail
cut to obtain titers for antibody responses against
oligomeric A.
Before the repeatable behavioral tests, mice were
habituated to the procedure 5, 4, and 3 days ahead.
The repeatable behavioral tests were performed; at
6 months (group 1–9), at 9 months (group 2, 3,
5, 6, and 7) and at 12 months of age (groups 3,
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5, 6, 7, and 10). These repeatable behavioral tests
consisted of: Open Field (OF), Novel Object Recog-
nition (NOR), Novel Location Recognition (NLR),
and Spontaneous Alternation (SA) test. One week
before sacrifice, a Morris Water Maze (MWM) test
was performed; at the age of 6 months (group 1, 4, 8,
and 9), at the age of 9 months (group 2) or at the age
of 12 (group 3, 5, 6, 7, and 10).
At sacrifice, mice were deeply anesthetized with
pentobarbital. Blood samples were collected by car-
diac puncture, serum was derived and stored at
–20◦C before sending to Intravacc to verify antibody
responses against oligomeric A and cyclic peptides.
The remaining blood sample were pipetted into a
1.5 ml Eppendorf tube with 20 l ethylenediaminete-
traacetic acid (EDTA) and kept on ice. Thereafter,
plasma was derived by centrifuging for 15 min at 4◦C
at 2000 g, and stored at –80◦C for later use. Brains
were dissected and processed for further immunohis-
tochemical analysis.
Vaccination and verifying immunization
The vaccine consisted of peptides cyclo[A22–28-
YNGK’], cyclo[A23–29-YNGK’], and cyclo[A
22–29-YNGK’] conjugated to tetanus toxoid (TTd).
As adjuvant an aqueous suspension of aluminum
hydroxide (Alhydrogel 2%, 10.3 mg Al3+/ml) from
Brenntag (Frederikssund, Denmark) and monophos-
phoryl lipid A from Salmonella enterica serotype
Minnesota Re 595 (Re mutant) was added. The mock
vaccine was prepared by capping bromoacetylated-
TTd with 2-aminoethanethiol and mixing purified
capped TTd with adjuvant. The vaccine and mock
vaccine were prepared, purified, and provided by the
Institute for Translational Vaccinology (Intravacc)
(Bilthoven, The Netherlands). For each batch, cyclic
peptides from the same original preparation were
freshly conjugated to TTd and adjuvant was added.
Mice were immunized by three subcutaneous
injections in the groin with either 0.3 ml triva-
lent peptide-TTd conjugate vaccine with adjuvant
(referred to as ‘immunized’ mice or vaccine) or 0.3 ml
mock-TTd with adjuvant (referred to as ‘mock-
immunized’ mice, or mock). In our previous study,
using this procedure, almost 80% of the immunized
mice displayed a specific immune response against
misfolded A (13). Fourteen days after the mice had
received their third immunization round, blood sam-
ples were collected by a tail cut (10–20 l per mouse).
Group 8–10 underwent no tail cut blood sampling.
At sacrifice blood samples were collected after heart
puncture (300 l). The blood samples were pipetted
into a SARSTEDT microvette CB 300 Z (SARST-
EDT AG & CO, Nümbrecht, Germany). Thereafter,
serum was derived from the blood samples by cen-
trifuging for 15 min at 4◦C at 2000 g. Subsequently
the serum was stored at –20◦C and sent to Intravacc
(Bilthoven, The Netherlands) for an enzyme-linked
immunosorbent assay (ELISA) to determine the anti-
oligo-A1–42 titers in tail samples and anti-cyclic
peptide titers as well as anti-oligo-A1–42 titers in
heart samples at sacrifice.
In a subset of mice, plasma levels of A1–42
were measured by ELISA (code 292-64501, WAKO,
USA), according to manufacturer’s procedures; The
kit is constructed as a sandwich ELISA format with
two kinds of antibodies. The monoclonal antibody
BNT77, which epitope is All–28, is coated on 96
well surfaces of a separable microplate and acts as a
capture antibody for Ax–42. Captured Ax–42 is rec-
ognized by another antibody, BC05 (Fab’ fragment),
which is specifically detects the C-terminal portion
of Ax–42, labeled with HRP. TMB is used as a read-
out and the reaction is terminated by the addition of
stop solution. The absorbance is then measured at
450 nm. For this, plasma from mice with highest or
with lowest A antibody titers within the immunized
groups was selected to evaluate plasma levels of A
of high responders ( = high titers) versus low respon-
ders ( = low titers). Samples of wild type mice served
as negative control.
Behavioral tests
Behavioral tests were performed in the active phase
of the mice (dark period) excluding the first and last
2 h of the active phase. All behavioral tests were
performed in dim light conditions. The mice were
habituated starting 5 days before the repeated behav-
ioral tests, also at 9 and 12 months, by transporting
the cage to the room and by handling the mouse for
30 s. This was repeated for 3 sequential days, once
a day. The tests were always performed in the same
sequence; OF, SA, NOR/NLR, MWM. Mice were
tested in random order. All tests were recorded by
EthoVision Version: 11.5 (Noldus Information Tech-
nology, Wageningen, The Netherlands). The OF and
MWM test were also live-tracked using EthoVision
Version: 11.5.
Day 1: Open field (OF)
The OF test was included for general exploratory
behavior (anxiety and locomotor activity). The open
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field box (50 × 50 × 35 cm) was divided in 3 zones;
border (30 × 10 cm), corners (10 × 10 cm), and cen-
ter (30 × 30 cm). The mouse was placed in the middle
of the box and exploring behavior was recorded for
5 min after the mouse had left the center area. After
each trial the box was cleaned with 70% ethanol and
dried before the next trial. The distance the mouse
moved was used as a measure for exploratory behav-
ior. The percentage of time the mice spent in the safe
zone; the corners was taken as the degree of anxiety.
Day 2: Spontaneous alternation (SA)
The SA test was included to give a reflection of the
spatial working memory. The SA test was performed
in a Y-maze with transparent arms with a length of
32 cm and a diameter of 6.5 cm each. The center of
the Y-maze consists of a circular area with a diam-
eter of 11 cm. Each mouse was placed in the center
of the Y-maze and exploring behavior was recorded
for 10 minutes, starting when the mouse entered the
first arm. An entry was considered complete when the
mouse has entered the arm with 4 legs and exits with 4
legs. Entries were recorded manually and the correct
alternations were calculated. A successful alternation
was defined as three consecutive entries into a new
arm before returning to the two previously visited
arms. After each trial the Y-maze was cleaned with
70% ethanol and dried before starting the next trial.
Percentage of successful alternations was calculated
by dividing the correct alternations by the possible
alternations (defined as the number of the total arm
entries minus two) and multiplied by 100. Mice that
had less than 20 entries in the 10 min test are excluded
from analysis.
Day 3: Novel object/Novel location recognition
(NOR/NLR)
The NOR/NLR test is representative for short-term
object recognition and spatial recognition. The same
box as for the OF test is used. Repeated NOR/NLR
tests in the same mouse required different sets of
objects, resulting in the use of three pairs during the
whole experiment. The NOR/NLR tests consist of
four trials of 5 min each: Habituation, Baseline, Novel
Object Recognition, and Novel location Recognition.
The mouse stayed in the box for the whole test.
In between the trials a pause of 45 s is introduced,
to clean the objects. The trial starts with habitua-
tion; the mouse is introduced in the middle of the
box and allowed to explore for 5 min. Subsequently,
two similar objects were introduced for the mouse
to explore. Then in random order, either one of the
objects is replaced by a novel one; NOR, or one of the
objects was relocated to another position; NLR. The
time spent exploring the two objects was recorded
for 5 min. The box was cleaned and dried before the
first trials and the objects were cleaned with 70%
ethanol and dried before introduction in the box. The
time exploring the objects was analyzed in E-line.
Preference was calculated by dividing the time spent
exploring the novel object or relocated object by the
time spent exploring both objects and multiplied by
100. Data of mice that had a total exploration time
less than 3% at baseline, or climbed on one of the
objects were excluded from further analyses.
Days 4–5: Morris water maze (MWM)
The MWM was performed to test long-term spatial
learning and memory as well as cognitive flexibil-
ity. The MWM test was only performed in the week
before sacrifice, as this test cannot be repeated with-
out bias. For the MWM, a pool with a diameter of
140 cm was used, which was virtually divided into 4
quadrants. Temperature of the water was maintained
at 23 ± 1◦C throughout the test. A white dye was
added to the water to visually distinguish the black
mouse from the water. A hidden platform, submerged
1–2 cm below the water level, with a diameter of
15.5 cm was placed in one of the quadrants; the target
quadrant for the training phases, and in the opposite
quadrant for the reversal test. The MWM consists of 8
training blocks, 1 probe trial, 1 relearning block, and
3 reversal blocks. The first day the mice had 2 train-
ing blocks with 4 h in-between. The following two
days, three training blocks with 3 h in-between were
given. Each training block consists of 3 trials, start-
ing at three different quadrants, excluding the target
quadrant containing the platform. The starting posi-
tions were randomly selected but differed between
the trials. Mice entered the trials with their nose fac-
ing the wall of the pool. For each trial a maximum of
2 min exploration was allowed. If the mice reached
the platform, it remained there for 10 s before taking
it out of the pool. When the mice did not find the plat-
form within the 2 min, the mice were gently guided to
the platform and maintained there for 10 s. Mice were
towel-dried between trials. After finishing one block
the mice were put under a heating lamp for ±15 min.
A learning curve is constructed from the average
latencies to reach the platform per block (training
session). The Area Under the learning Curve (AUC)
is used to statistically compare the different groups.
A non-successful learner is a mouse that could not
find the platform in at least 5 out of the 8 training
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sessions, from which at least 2 in the last 3 sessions.
The probe trial test was performed 24 h after the last
training block. In the probe trial the platform was
removed and the mice were put in the pool for 100 s.
All the mice entered the pool at the quadrant opposing
the target quadrant. The time spent by the mouse in
the target quadrant and the number of platform cross-
ings was measured. Immediately after the probe trial,
a relearning block was performed to train the mice
to search for the platform again. In the relearning,
the platform was placed back in the target quadrant
and 1 training block with 3 trials was executed. The
last day a reversal test is performed. Reversal learn-
ing is considered to examine cognitive flexibility.
In the reversal learning, the platform was moved to
the opposite quadrant. Subsequent, three blocks with
each 3 trials, excluding the new target quadrant as
start position, were executed. Memory consolidation
was calculated as the difference between the latency
of the relearning block and the first reversal training
block.
Sacrifice
At sacrifice, mice were transcardially perfused
to collect brain tissue free of blood. For that,
mice were deeply anesthetized with pentobarbital;
the heart was punctured to collect blood sam-
ples. Subsequently, mice are perfused with saline
until the liver discolored, followed by perfusion
with 4% paraformaldehyde in 0.1 M PBS. Brains
were dissected and post-fixated for 24 h in 4%
paraformaldehyde in 0.1 M PBS and rinsed for 3
days (4 times) in 0.01 M phosphate buffered saline
(PBS, pH 7.4). To prevent freezing damage, brains
were dehydrated in 30% sucrose in PBS overnight
at room temperature before freezing with liquid




To examine the effect of active immunization
on plaque formation in the brain, a 6E10 stain-
ing was performed. 6E10 binds to amino acid
residues 1–16 of A, and hence does not distin-
guish between the different forms of A (APP,
linear, oligomeric fibrillary). The epitope lies within
residues 3–8 (EFRHDS). A monoclonal mouse anti-
amyloid beta 1–16 antibody was purchased from
Biolegend (San Diego, CA, USA). The Biolegend’s
beta amyloid antibody clone 6E10 binds to the
abnormally processed isoforms, as well as precur-
sor forms. Secondary goat anti-mouse was purchased
from Jackson ImmunoResearch Inc (West Grove, PA,
USA). After the staining, stitched photographs (50×)
were processed for manual analyses of plaque load;
plaques were counted regarding number, size and
location (Image-Pro Plus version 6, Media Cybernet-
ics, Rockville MD, USA). Plaque load was calculated
as number times size per section.
Neuroinflammation
Neuroinflammation was investigated by immuno-
histochemistry in subsets of mice. Mouse brains
were cut in 20 m thick sections. Prefrontal cortex
(PFC) (Bregma 2.34 – 1.54) and dorsal hippocam-
pus (DHC) (Bregma –1.34 – 2.18) sections were
stained to visualize microglia. To examine the mor-
phological features of microglia in the mouse brain,
DHC and PFC sections were stained using antibod-
ies against ionized calcium binding adaptor molecule
1 (Iba 1), a 17 kDa protein which in the central ner-
vous system is specific for microglia. Sections were
washed 3 times in 0.01 M PBS, endogenous per-
oxidases were blocked using a 0.3% H2O2 (Merck
Darmstadt, Germany) solution in 0.01 M PBS for
30 min. Sections were washed in 0.01 M PBS and
subsequently incubated for 72 h at 4◦C in Rabbit anti-
Iba-1 (Wako Pure Chemical Industries, Osaka, Japan)
at 1:2500 dilution in 1% BSA (Sigma-Aldrich, St.
Louis MO, USA) in PBS containing 0.1% Triton
X-100 (Merck Darmstadt, Germany). After wash-
ing, Biotin-SP-Goat anti-Rabbit antibody (Jackson
ImmunoResearch, Suffolk, UK) in a 1:500 dilution
in 0.01 M PBS was added for 2 h at room temper-
ature. After washing, Vectastain Elite ABC HRP
Kit (Vector Laboratories, Burlingame, Ca, USA) in
1:500 dilution in PBS which was added to the sec-
tions and after washing again, DAB (Sigma-Aldrich,
St. Louis, MO, USA) was used for counterstaining.
Images were taken using an Olympus BH2 micro-
scope with a Leica DFC280 camera, software used
was Leica Qwin V3. Iba1 photos were taken at 200
magnification of the CA1, CA3, dentate gyrus inner
blade, hilus, and in the prefrontal cortex. Iba-1 pic-
tures were analyzed using Image-Pro Plus version 6
image software (Media Cybernetics, Rockville MD,
USA) according to the protocol as described previ-
ously [16]. Microglia activity, calculated as cell body
area/total cell area, was obtained as a measure for
neuroinflammation.
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Neurogenesis
Neurogenesis was obtained from doublecortin
(DCX) staining of dorsal hippocampal sections [17].
Sections, 20 m, were washed twice in 0.01 M PBS
before blocking endogenous peroxidases by 20 min
incubation in 3% H2O2 in PBS after which the sec-
tions were washed again 4 times in 0.01 M PBS.
Sections were blocked by 1 h incubation in 5% nor-
mal rabbit serum (NRS) in 0.01 M PBS, which is
removed, followed by adding the primary antibody,
goat anti doublecortin (DCX, Santa Cruz, Santa Cruz,
CA, USA) at 1:4000 dilution in 0.1% Triton X-100,
1% BSA, 1% NRS in 0.01 M PBS. Primary antibody
is incubated at 37◦C for 3 h, followed by overnight
incubation at room temperature, followed by 3 nights
at 4◦C. After washing 5 times the secondary antibody,
rabbit anti goat (Jackson ImmunoResearch, Suffolk,
UK) was added at a 1:500 dilution in 0.1% Triton X-
100, 1% BSA in 0.01 M PBS and incubated overnight
at 4◦C. Washed 5 times and added Vectastain Elite
ABC HRP at 1:500 dilution in 0.01 M PBS for 2 h
at room temperature, washed 3 times, left for 2 h
and incubated overnight at 4◦C. DAB enhanced with
ammonium nickel sulfate hexahydrate was used for
counterstaining. DCX photos were taken at 50 magni-
fication using the Leica microscope system, imaging
the entire dentate gyrus at this magnification. The area
of DCX positive cells per length of the dentate gyrus
was used as measure for neurogenesis.
Brain derived neurotrophic factor
Brain function was estimated from brain-derived
neurotrophic factor (BDNF) expression in non-
treated 6 months mice. BDNF was stained in
free-floating dorsal hippocampus slices, which were
first incubated for 20 min at room temperature with
3% H2O2 and subsequently washed with 0.01 PBS.
Slices were then incubated for 1 h at room temper-
ature with 0.01 PBS containing 2% normal goat
serum (Bio-Connect Life Sciences, Huissen, The
Netherlands) and 1% BSA to reduce aspecific stain-
ing. Slices were subsequently incubated for 3 h at
37◦C with rabbit anti-BDNF antibody (Alomone,
Jerusalem, Israel) in a 1:1000 dilution in PBS contain-
ing 1% BSA and 1% normal goat serum. Afterwards,
slices were kept overnight at room temperature after
which they were transferred to a cold room of 4◦C.
After three nights, slices were washed and incubated
overnight at 4◦C with secondary goat anti-rabbit anti-
body in a 1:500 dilution in PBS containing 1% BSA.
The following day, slices were washed and incu-
bated at room temperature for 2 h with avidin-biotin
complex in PBS. Slices were then washed and kept
overnight at 4◦C. The next day, DAB was added and
activated with 0.1% H2O2. Slices were incubated
until specific staining could be observed and were
mounted on slides the next day. Pictures were taken
at a 100× magnification. Within the dorsal hippocam-
pus, pictures were taken of the CA1 and CA3 regions.
Optical density of the BDNF staining in the stratum
pyramidale of the CA1 and CA3 region was measured
using Leica LAS Macro Editor software. The optical
density of the stratum radiatum of the CA1 and CA3
region was used as a measure of background staining
and was subtracted from the optical density of the
stratum pyramidale.
Data analyses
Statistical analyses were performed using IBM
SPSS Statistics Version 22. To verify J20 mice as
model for AD, comparison of results of 6-month-old
non-treated J20 with wild type were analyzed using
an Independent-Samples T-test. Overall comparison
of early treated groups was performed with a 2-way
ANOVA, with age and treatment as factors. In case
of significant effects in repeatable tests, effects were
subsequently confirmed by comparing appropriate
groups in an ANOVA for repeated measurements.
A One-Sample T-test was used for calculating the
difference of each group from chance level in the
NOR/NLOR tests. Data of the later immunized and
mock-immunized mice (regression study) were com-
pared using an Independent-sample T-test. Behav-
ioral data from the prevention study (early vaccina-
tion) at 12 months, and the treatment study (delayed
vaccination) at 12 months were compared with a
2-way ANOVA, with prevention/regression and treat-
ment as factors. All error bars shown in the figures
represent the Standard Error of the Mean (SEM) and
p < 0.05 was considered statistically significant.
As mice from some different experimental groups
had exactly the same experience at certain time
points, for these time points data were pooled. For this
reason, 6 months repeated tests outcomes in treatment
groups 1, 2, and 3 are combined and will be referred
to as the 6 months vaccine groups, while treatment
groups 4 and 5 will represent the mock group. Simi-
larly, data of group 6, 7, and 8 will be referred to as 6
months J20 non-treated mice. Group 9 is representa-
tive for wild type 6 months in the repeated behavioral
test. At 9 months, data for repeated tests of group 2
and 3 (vaccine) were combined and compared to data
of group 5 mock.
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Table 1
Premature mortality among the experimental groups
Group Treatment Premature mortality
1 6 months J20 vaccine prevention 1/35 (2.9%)
2 9 months J20 vaccine prevention 5/35 (14.3%)
3 12 months J20 vaccine prevention 2/35 (5.7%)
4 6 months J20 mock prevention 1/25 (4.0%)
5 12 months J20 mock prevention 2/25 (8.0%)
6 12 months J20 vaccine regression 2/35 (5.7%)
7 12 months J20 mock regression 5/25 (20.0%)
8 6 months J20 non-treated 0/15 (0%)
9 6 months wild type non-treated 0/15 (0%)
As group 10 (wild type) has been added later to
check whether 12-month-old mice could perform in
our behavioral tests, although litter mate mice did
not undergo the exact same procedures; for that this
group is not statistically compared to other groups.
RESULTS
General
From the 257 mice collected from the breeding
facility, 2 mice did not look healthy and were omitted
before entering the study. As anticipated, 255 mice
were included in the study. Seventeen mice died and
one mouse had to be sacrificed prematurely, during
the course of the experiments. Table 1 presents mor-
tality among the different groups. Deaths occurred at
different stages of the protocol; before entering exper-
iment (n = 6), before vaccination rounds (n = 8), after
vaccination rounds (n = 2), and in-between behavioral
testing (n = 2). No striking differences were observed
between groups. Six mice were excluded because of
inconclusive genotype. Two mice in the non-treated
wild type group displayed a human APP band in
genotyping after sacrifice, and again by retry, and
were hence translocated to the non-treated J20 group.
J20 mice as model for AD
In literature, J20 mice could display signs of cog-
nitive problems from the age of 6 months. To verify
that our J20 mice could indeed be used for evaluating
the effects of immunization, firstly non-treated J20
mice (group 6, 7, and 8 in case of repeatable tests and
only group 8 for the MWM) at 6 months of age were
compared to their non-treated wild type littermates
(group 9), regarding their AD phenotype. Results
from behavioral tests are summarized in Fig. 2, and
show hyperactivity without increased anxiety in the
OF test; hyperactivity, but impaired working mem-
ory in the SA test; no impaired NOR, but impaired
NLR; and impaired spatial learning (longer latency)
and memory in the MWM test. As spatial learning
and memory were severely impaired in J20 mice,
results from the reversal test in the MWM would
not provide a relevant measure for cognitive flexi-
bility, and therefore was not presented here. Hence,
results confirm AD-like phenotype in J20 mice at 6
months of age. Moreover, these 6-month-old J20 mice
showed plaque formation, and displayed significantly
lower neurogenesis and BDNF levels compared to
wild type, but at similar microglia activity (Table 2).
Effects of early vaccination on behavior
Exploration and anxiety in the open field (OF)
The way the mice act in the open field expresses
general exploratory and anxiety behavior. Time
spent in the safe zone, the corner, was signifi-
cantly increased with aging (p = 0.009) but no effect
of treatment could be observed. Similarly, explo-
ration measured as distance moved, was significantly
decreased with aging (p < 0.001) without effect of
treatment (Fig. 3).
Working memory: Spontaneous alternation (SA)
The number of entries showed a slight, but signifi-
cant (p = 0.050) age-related reduction, with no effect
of treatment. Correct alternations as percentage of
number of entries was used as a measure for work-
ing memory. The percentage of correct alternations
appeared significantly improved by immunization
(p = 0.029). The effect of treatment was confirmed
with ANOVA for repeated measurements within
the same mice (group 3 versus group 5; p = 0.04)
(Fig. 4), with the vaccinated mice performing
almost at the level of 12-month-old wild type mice
(SA = 61.7 ± 2.2%).
Short-term memory: NOR/NLR
Short-term memory function was obtained from
a NOR and NLR test. In neither test, signifi-
cant differences regarding age or treatment were
observed. However, whereas J20 could recognize
the Novel Object, irrespective of age or treat-
ment (6 months mock: 58 ± 3%; 6 months vaccine:
60 ± 3%; 9 months vaccine: 61 ± 3%; 12 months
mock: 60 ± 3%; 12 months vaccine: 57 ± 3%, all
significantly different from 50%), Novel Location
Recognition was better at all ages (repeated measure-
ments) in 12 months vaccinated compared to mock
treated mice (64 ± 3; 60 ± 3; 61 ± 3% in 6-, 9-, and
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Fig. 2. Evaluation of behavioral comparison between non-treated J20 mice and their wild type littermates at 6 months of age. A, B)
Exploratory behavior and preference for the safe area of the open field, respectively. C, D) Total number of arms entered and % correct
alternations, resp., in the spontaneous alternation test. E) Preference for the novel object in the Novel Object Recognition test (NOR) and
F) preference for the relocated object in the Novel Location Recognition test (NLR). G) Area under the spatial learning curve as latency to
find the platform (AUC). H) Spatial memory as the time spent in the target quadrant of the Morris Water maze test. *significant difference
between J20 and wild type.
Table 2
Immunohistochemical parameters obtained in the hippocampus of 6-month-old non-treated
J20 and wild type littermates
Wild type J20
N 11 12
Microglia activity hippocampus (cellbody/cellsize %) 10.0 ± 0.3 10.9 ± 0.4
Double Cortin (area/length) 2.5 ± 0.2 1.8 ± 0.2∗
BDNF (OD) 43.3 ± 4.9 32.3 ± 4.6∗
OD, optical density; BDNF, brain-derived neurotrophic factor. ∗significantly different from wild
type.
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Fig. 3. Results of the open field test in immunized and mock-immunized mice at different ages. A significant effect of aging was observed
for the distance moved (A) as well as for preference for the safe zone; the corner (B), however, without effects of treatment.
Fig. 4. Serial measurements of spontaneous alternations as mea-
sure for working memory in the same mice shows a significant
improvement after vaccination at 12 months. The number of arms
entered in the spontaneous alternation test showed significant age-
related decline, without effect of treatment. *significant difference
between vaccinated and mock treated mice.
12-month-old vaccinated mice, resp. n = 31, versus
56 ± 4; 57 ± 3; 58 ± 3% in 6-, 9-, and 12-month-old
mock treated mice, resp., n = 22).
Spatial learning in the MWM
When spatial learning curves of mice that received
vaccination or mock (group 1–5) were compared,
results showed a significant effect of age (p = 0.009),
but no effect of treatment, nor a significant interac-
tion between the two factors. Although borderline
statistically significant (p = 0.051), 12-month-old
vaccinated J20 mice perform worse than 12-month-
old mock mice (Fig. 5A). After learning, vaccinated
mice found the platform in 104 ± 6 s, while mock
mice found it in 86 ± 9 s. Furthermore, the percent-
age of mice that successfully could learn in the MWM
declined with age; whereas at 6 months, 62% of vac-
cinated and 65% of mock treated mice could learn the
position of the platform, at 12 months, 48% of mock
and only 25% of vaccinated mice were successful.
For comparison, AUC of the learning curve of 12-
month-old wild type mice was 700 ± 63 s, with 78%
successful learners.
Spatial memory (MWM)
Overall comparison of spatial memory in the
groups treated with early vaccination or mock did
not reveal any statistical differences regarding effects
of aging, treatment, or interaction, neither in time in
target quadrant, nor in number of crossing over the
previous position of the platform. However, although
not statistically significant, the results regarding
platform crossings may indicate improvement at
6 months, but deterioration at 12 months of age
(Fig. 5B) in vaccinated mice. Time in target quad-
rant did not exceed chance level (25%) for any of
the treated groups, whereas wild type mice could
remember the platform position at 6 months (32 ± 4%
in target quadrant and 3.3 ± 1.1 platform crossings;
N = 13) as well as at 12 months (39 ± 7% in target
quadrant and 2.2 ± 1.0 platform crossings). Never-
theless, if mice do not learn the position of the
platform successfully (Fig. 5A), it is not surprising
that they also would not remember its position in
the probe trial. However, if only mice that actually
learned the position of the platform are considered,
overall performance improved, but vaccinated mice
still performed worse than mock.
Memory consolidation (MWM)
If mice had learned the position of the platform
well, they may be more confused when it is relocated
to another position; memory consolidation. Mem-
ory consolidation showed a significant age-related
decline (p = 0.017), without a significant effect of
vaccination versus mock (Fig. 5C).
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Fig. 5. Results obtained in the Morris Water Maze. A) Spatial learning as area under the curve (AUC) of latency to find the platform and B)
spatial memory as the number of times mice swam over the previous position of the platform. C) Memory consolidation. D) AUC of latency
to find the relocated platform in reversal learning. Note that although not statistically significant, all parameters indicate worse performance
in 12-month-old vaccinated compared to mock treated mice.
Cognitive flexibility (MWM)
Cognitive flexibility is obtained from the AUC of
the learning curve in the reversal learning trial, in
which the platform is relocated to the opposite quad-
rant. Comparing results of all early treated groups,
no effect of age was observed, but treatment gave
a trend (p = 0.079) with vaccinated mice performing
worse compared to mock (Fig. 5D). No interaction
effect was seen.
The relevance of this test, however, is questionable
as groups showed already differences in learning and
memory of the position of the platform.
Immunohistochemistry
Aβ plaques
A presence was stained with 6-E10. This stains
all forms of A, from the precursor to the actual A
plaques. An example is shown in Fig. 6A. The figure
shows background staining; probably APP, as well
as dark spots; A plaques, in different brain areas in
J20 mice. Plaques mainly occurred in the hippocam-
pus and cortex. Figure 6B and C shows plaque load in
the whole brain section, as well as specifically in the
hippocampal area. There is a significant age-related
increase in plaque load (p = 0.002), but no signifi-
cant effects of treatment, nor interaction. Changes in
plaque load could be attributed to both increases in
size as well as in number of plaques.
Neither total plaque load nor hippocampal plaque
load was significantly correlated to any of the cogni-
tive parameters. However, hippocampal plaque load
was significantly correlated to parameters obtained in
the open field test (see Table 3).
Neurogenesis
Neurogenesis is determined by the double cortin
(DCX) positive area in the hippocampus (Fig. 7C).
Neurogenesis was significantly decreased with aging
(p < 0.001) without effect of treatment, nor inter-
action. Neurogenesis was significantly correlated
negatively to total plaque load (r = –0.34, p = 0,033),
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Fig. 6. A) Example of 6-E10 staining of A in brain sections of wild type mice (left panel) and J20 mice (right panel), showing more
background staining and appearance of A plaques in J20 mice. Total plaque load (B) and specific plaque load in the hippocampus (C) in
the different experimental groups is presented in the lower panel.
Table 3
Regressions between open field (OF) test parameters, and total




R p r p
OF distance –0.38 0.000 –0.14 0.090
OF corner 0.17 0.045 0.11 0.107
OF center –0.19 0.028 –0.19 0.025
but not with hippocampal plaque load. Moreover,
neurogenesis was not correlated to any of the param-
eters of the cognitive tests, but appeared significantly
correlated to distance in the open field (r = 0.43,
p = 0.006).
Neuroinflammation
Neuroinflammation is measured as microglia
activity. This parameter was calculated from mor-
phological changes as cell body area/total cell size.
In the hippocampus as well as in the prefrontal cor-
tex, a significant age-related increase in microglia
activity was observed, without significant effects of
treatment nor interaction (Fig. 7A, B). Microglia
activity in the hippocampus was negatively correlated
to neurogenesis (r = –0.46, p = 0.019) and positive to
plaque load (r = 0.55, p = 0.001). Whereas for all mice
no associations were observed for microglia activity
and behavioral performance, when focusing on only
the 12-month-old vaccinated mice and their mock
controls, a highly significant correlation was seen
between hippocampal microglia activity and AUC of
the MWM learning curve (r = 0.78, p = 0.008), which
could completely be attributed to microglia activity
in the Hilus (r = 0.93, p < 0.000).
Aβ metabolism
Antibody titers for the cyclic peptides as well as
for A1–42 were measured at Intravacc. Results are
presented in Table 4, and show a good and persis-
tent response to the peptides at sacrifice in all age
groups, though significantly declining with aging.
However, antibody responses toward A in immu-
nized mice at sacrifice did not exceed the background
values seen in mock treated mice. A antibody titers
measured in tail samples, collected 2 weeks after
the last immunization in all mice treated at young
age, revealed a slight positive response in favor of
immunized mice (mock:1.17 ± 0.22 versus vacci-
nated 1.63 ± 0.16, p = 0.047). Immunization at later
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Fig. 7. Neuroinflammation measured as microglia activity in hippocampus (A) and prefrontal cortex (PFC) (B) in the different experimental
groups (n = 5–10 per group). C) Measurement of Double Cortin (DCX) positive area in hippocampus, as measure for neurogenesis (n = 8 per
group).
Table 4
Antibody titers of responses against cyclic peptides or A in serum samples collected at the time of sacrifice
6 months 9 months 12 months
mock vaccine mock vaccine mock vaccine
C(22–28)BSA 2.1 ± 0.3 4.7 ± 0.1 NA 4.3 ± 0.1 1.0 ± 0.3 3.8 ± 0.1
C(23–29)BSA 2.1 ± 0.4 4.9 ± 0.1 NA 4.5 ± 0.1 1.4 ± 0.3 4.1 ± 0.1
C(22–29)BSA 1.5 ± 0.4 4.6 ± 0.1 NA 4.2 ± 0.1 1.3 ± 0.3 3.9 ± 0.1
A 2.2 ± 0.3 1.9 ± 0.3 NA 3.0 ± 0.2 2.5 ± 0.3 2.4 ± 0.3
ages, regression study, showed the same results (Sup-
plementary Table 2). When taking the results of tail
samples from all immunized mice together, including
early as well as delayed vaccination, the significantly
increased A antibody titers in immunized mice ver-
sus mock (1,69 ± 0.14, N = 126 versus 1.22 ± 0.18,
n = 64; p = 0.019) suggest a positive A response of
only short duration (2 weeks).
To further elucidate on the effects of A, in sub-
groups of mice; 6-month-old wild type (random),
6-month-old non-treated J20 (random), 6-month-old
mock treated J20 (random), 6-month-old vaccine
treated J20 (6 mice with the highest and 6 mice
with lowest anti- A antibody titers), 12-month-old
mock treated mice (random), and 12-month-old vac-
cinated mice (6 mice with the highest and 6 mice with
lowest anti- A antibody titers) circulating levels
of A1–42 were measured. Results showed a strain-
related increase in circulating A, independent of
age, treatment or antibody titers (Table 5).
Effects of late vaccination
In order to investigate whether vaccination still
may have an effect once cognitive decline and
plaque formation has been established, J20 mice
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Table 5
Plasma levels of A 1–42 in the different experimental groups.
Vaccinated mice were separated into mice with high and mice
with low A titers
6 months
Wild type (n = 3) 6.4 ± 1.5 pM
Non-treated J20 (n = 12) 25.8 ± 1.3 pM
J20 mock (n = 12) 25.1 ± 1.3 pM
J20 vaccine low titers (n = 7) 23.9 ± 2.3 pM
J20 vaccine high titers (n = 6) 24.2 ± 1.9 pM
12 months
J20 mock (n = 11) 22.3 ± 1.1 pM
J20 vaccine low titers (n = 6) 25.4 ± 1.6 pM
J20 vaccine high titers (n = 7) 25.9 ± 1.6 pM
were vaccinated later in life and compared to mock
vaccination. No difference between mock and vac-
cine mice were seen for any of the behavioral
parameters (Fig. 8). Moreover, no significant differ-
ences were observed when comparing these delayed
treated mice to the early treated mice at 12 months
of age. Similarly, no differences were observed
in immunohistochemical parameters (Supplementary
Table 1). Similar to early vaccination, a good antibody
response to the cyclic peptides without antibodies
against A were observed (Supplementary Table 2).
DISCUSSION
Active immunization against oligomeric A could
be a promising step in the development of therapy
against AD. A novel concept vaccine of small cyclic
peptides mimicking the specific molecular bend in
the structure of oligomeric A, conjugated to TTd,
induced antibodies specifically against the misfolded
oligomeric A in mice [12]. A subsequent in vivo
study in mice [13], confirmed a specific immune
response against misfolded A, and significantly less
oligomeric A–induced cholinergic fiber loss, after
vaccination with these peptides. In the present study,
the therapeutic potential of these cyclic A peptide
conjugates was investigated in J20 mice as model for
AD. J20 mice showed an age-dependent AD-like phe-
notype; cognitive decline and A plaques, supporting
the relevance of this mouse model for our study on
the effects of active immunization against oligomeric
A.
Vaccination at young ages seemed to prevent
short-term working memory loss, but deteriorated
long-term spatial learning and memory, at later ages.
The absence of a significant antibody response to A
despite a persisting response to the cyclic peptides,
may exclude a mediating role of A in these cogni-
tive effects. Active immunization at later ages, when
the AD-like phenotype was established, did not affect
cognition nor A pathology. Hence, we conclude that
despite the clear and straightforward rational behind
the development of the concept vaccine used in the
present study, it does not appear to have the antici-
pated anti-A effects. Still, cognitive performance
was affected by early, but not late, vaccination. For
late vaccination, the period between vaccination and
behavioral testing may have been too short to exert
effects on cognitive performance.
J20 mice as model for AD
The behavioral phenotype of our J20 mice was
compared to their wild type littermates to verify an
AD-like phenotype that could be demonstrated with
our test battery. Indeed, in agreement with literature
[14], 6-month-old J20 mice displayed overall cogni-
tive decline. Significant plaque development support
presence of enhanced A expression. No age-related
mortality was observed up to 12 months. Results
from wild type littermates indicated that mice rang-
ing from 6 to 12 months of age could perform well
in the behavioral tests, supporting that the tests are
suitable for this age range. Moreover, for most param-
eters an age-related deterioration was observed in J20
mice, indicating age-related development of an AD
phenotype. The observed features of the model are
in general agreement with previous studies [18–21].
From the above results we concluded that the J20
mice provide a relevant model to study the effects of
active immunization against oligomeric A.
The concept vaccine
A promising way to prevent AD is to promote the
removal of aggregated A proteins through vaccina-
tion against oligomeric A [22]. When A proteins
aggregate, they undergo a conformational change
from a relatively linear protein to a protein with a
bended conformation. This misfolded oligomeric A
has been shown to directly promote apoptosis of neu-
rons in the brain, resulting in the neurodegeneration
in AD [23]. Furthermore, accumulation of oligomeric
A leads to oxidative stress, neuroinflammation, loss
of synapses and synaptic plasticity in the brain [5,
23]. These soluble A peptides can form fibrils, that
arrange themselves into -pleated sheets to form
insoluble fibers that are deposited as extracellular and
perivascular amyloid plaques. Active immunization
against the oligomeric A could potentially delay or
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Fig. 8. Behavioral data of the mice vaccinated or mock treated at 9, 10 and 11 months of age in order to study effects on regression. No
effects of late vaccination were observed. AUC, area under the curve; NO, Novel Object; NL, Novel Location.
reverse the aggregation processes and hence dimin-
ish the cognitive dysfunction [7, 8]. Hoogerhout
and co-workers [12] developed a concept vaccine of
cyclic A peptides that mimic the bend in misfolded
oligomeric A. As this bend is not present in APP
or normal linear A, indeed the vaccine was shown to
be specific for the aggregated and pathological forms
of A [12]. This specificity prevents (over)activation
of the immune system when no aggregated A is
present, and limits interference with the normal phys-
iological function of A. The linear form of A may
even have neuroprotective properties, as it can mod-
ulate long-term potentiation and plays a role in the
innate immune system [24–26]. (Over)activation of
the immune system has been an issue with previ-
ous vaccines. A phase II trial using the A vaccine
AN1792 was discontinued as 6% of patients devel-
oped meningoencephalitis [9, 27]. This was linked
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to T-cell mediated inflammation, as A1–42 vaccine-
activated T-cells infiltrated into the brains of patients
[28]. In our previous study, immunization with the
new concept vaccine [12] diminished neurodegener-
ation induced by oligomeric A in mice [13]. In the
present study, we investigated whether the protective
effects of this concept vaccine could be extended in
a mouse model for AD.
Active immunization to prevent AD-like
phenotype
Cognition
To examine whether vaccination at young ages can
delay or prevent an AD-like behavioral phenotype
at later ages, J20 mice were immunized by 3 injec-
tions, at 2, 3, and 4 months of age. Cognitive behavior
was evaluated at 6, 9, and 12 months of age. Since
our J20 mice showed an age-dependent cognitive
decline from 6 to 12 months of age, improved cogni-
tive performance was anticipated in vaccinated over
mock-vaccinated mice. Whereas, at 6 and 9 months of
age no differences were observed between vaccinated
and mock-treated mice yet, at 12 months differences
became more apparent. At 12 months of age, working
memory, measured as percentage correct alterna-
tions in the Y-maze, was significantly improved by
vaccination. An improved working memory may be
supported by the findings in the novel location test for
short term spatial memory; though not significantly
different from mock, vaccinated mice performed
significantly above chance level, whereas their 12-
month-old mock control did not. In contrast, spatial
learning, as latency to find the platform in the MWM,
seemed to deteriorate faster with aging in vacci-
nated than in mock-treated mice, resulting even in
an impaired learning curve at 12 months in vacci-
nated compared to mock mice. Moreover, the number
of mice capable of learning this task anyway was
about twice as low in the vaccinated compared to the
mock group. As the mice did not learn the position
of the platform, subsequent spatial memory (plat-
form crossings) was also impaired, and hence results
from a reversal trial have no relevance for cognitive
flexibility. Interestingly, the mixed cognitive effects
observed in the present study showed striking resem-
blance with the competitive short-term and long-term
spatial memory processes described by Sanderson
and Bannerman [28]. An improved gluA1 AMPA
receptor dependent working memory, and a deteri-
orated gluA1-independent MWM performance [29],
suggests a role for gluA1 AMPA receptors in our
cognitive findings. Intracellular levels of oligomeric
A have been reported to regulate gluA1 subunit of
AMPA receptors [30]. Although we did not observe
effects of vaccination on extracellular A (plaques or
circulating levels), we cannot exclude effects through
changes in intracellular A levels though. Although
in literature, most of the studies present positive effect
of vaccination [31–35], accurate comparison is ham-
pered by the use of different models, different time
schedules, different vaccines and/or adjuvants, and
last but not least different behavioral tests. More-
over, a publication bias, negative outcomes are less
often published, may have contributed to the overall
indicated positive effects. Still, potential deleterious
effects of vaccination through interference with the
immune system are also recognized [32]. Neverthe-
less, in the present study a mixed positive/negative
effect of vaccination at 2, 3, and 4 months of age
on cognition became apparent only at 12 months
of age.
Aβ metabolism
Vaccination started at 2 months of age, anticipat-
ing no substantial plaques load yet [14]. Whereas at
6, 9 and 12 months, a significant antibody response
to the cyclic peptides confirmed accuracy of the vac-
cination protocol, antibody responses to A did not
exceed background levels. Only 2 weeks after the
last vaccine/mock injection a significant but mild A
response in favor or immunized mice was observed,
suggesting at the most a short-lasting A response.
This is in agreement with our previous study [13],
showing a slight, but significant increase in antibody
titers against A, 12 days after the last immunization
round. While plaque load showed an age-dependent
increase from 6–12 months of age, no effect of
vaccination was found. Hence, our hypothesis that
vaccination would reduce oligomeric A levels, and
hence decrease plaque load, can be rejected. In con-
trast, Schenk and co-workers [33, 34] did show effects
on amyloid pathology after vaccination, using syn-
thetic human A42.
Although overexpression of APP is supposed to
be brain-specific in the J20 mice [14], plasma levels
of A1–42 were increased as well, and A1–42 may
have been transported out of the brain. If we con-
sider an equilibrium between circulating and brain
A, we would expect age differences, as plaque load
increased with age. If circulating levels represent
the amount of A that is extruded from the brain,
absence of effects of age or treatment on plasma lev-
els may then indicate that this A transport in J20
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mice may have reached its limits already at 6 months
of age.
Finally, no correlation was found between A
pathology and cognition, suggesting no causal rela-
tionship between the two AD hallmarks. A similar
lack of association has been described in other trans-
genic mouse models [36] as well as in patients.
Neuroinflammation/neurogenesis
Proliferation and activation of microglia in the
brain is a prominent feature of AD [37]. Microglia
activation associated with plaque formation could
be harmful to neurons, by means of synaptic prun-
ing and/or (over)production of pro-inflammatory
cytokines, but microglia activity may also protect
against AD, since decreased microglia activity is
associated with increased AD risk [37]. Neuroin-
flammation in the present study is obtained from
morphological measurement of microglia activity as
cell body to cell size ratio [16]. In 6-month-old
J20 mice, significant plaque load with concomi-
tantly decreased cognitive function, did not coincide
with microglia activation yet. In contrast, Wright
and co-workers [21] suggested that neuroinflam-
mation precedes plaques deposition. Yet similar to
the present study, a very recent study indicated no
microglia activity at 6 months, but also not at 12
months of age [38]. As expected, microglia activity
increased with age, however irrespective of treat-
ment. If anything, at 12 months, microglia activity
is higher (p = 0.079) in vaccinated versus mock mice.
Although activated microglia can cluster around A
plaques, their role is not completely clear. In an ele-
gant study in mice, Baik and coworkers [39] showed
that apart from eating the plaque away, microglia
could also contribute to plaque growth by consolida-
tion of newly generated plaque clusters in the vicinity
of existing plaques. Hippocampal microglia activity
was negatively correlated to spatial learning in the
MWM suggesting a detrimental rather than a support-
ing role for microglia activity in the present study.
Furthermore, no overall correlations were observed
with immunohistochemical parameters and cognitive
behavior. Hippocampal microglia activity was nega-
tively correlated to neurogenesis, and neurogenesis
was significantly correlated to plaque load, suggest-
ing neurodegenerative processes coupled within the
brain. Nevertheless, since neither circulating levels
of A, nor plaque load were affected by vaccination,
behavioral changes seem to be attributed to mecha-
nisms other than altered A pathology.
Active immunization to reverse already
developed AD-like phenotype; regression
For this part of the study, J20 mice were vaccinated
or mock treated at 9, 10, and 11 months of age
and evaluated at 12 months old. For none of the
measured parameters significant differences between
immunized and mock immunized were observed.
This result may indicate that by active immuniza-
tion, an already developed AD-like phenotype in
J20 mice cannot be rescued. These results are in
contrast to effects of Enoxaparin treatment [40]
or immunization with A1–42 [33] in mice with
sustained plaque formation. On the other hand, time
between vaccination and evaluation (1 month) may
have been too short to exert an effect. Based on
the studies of Wright et al. [21], we anticipated
cognitive improvement and plaque reduction after
early vaccination, to be seen at 6 months of age, and
either persisting or waning at later ages. However, it
took 8 months for cognitive improvement to become
visible after early vaccination. Accordingly, a longer
time between delayed vaccination and analyses
could have provided a more complete answer on
effectiveness of delayed vaccination.
Clinical perspective
Although we do realize that translation of data from
animal studies into the human situation is at the least
challenging [41] as AD-like phenotypes in mice are
usually artificially induced and mimic only one or a
few aspects of AD in humans, we are still able to learn
from these results.
Active immunization makes use of the subjects
own immune system to remove the unwanted factors.
An important advantage of this prophylactic therapy
is that the senescent immune system present in elderly
is circumvented. In a proper immune response, the
new antigen induces specific activation of effector-
T-cells, with a short life span, but a subset of these
T-cells has the potential for long-term survival; the
memory-T-cells [42]. Essential features for these
cells are: prior activation by a novel antigen, persis-
tence in absence of cognate antigens and enhanced
functional activity upon re-exposure. In case of the
present study, we speculate that the memory T-cells
may not function optimally, as none of the above fea-
tures may be optimal; no clear first-time presentation
of the antigen during vaccination, as the oligomeric
A (epitope) may already be present in low levels; no
persistence in the absence of antigen as the oligomeric
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A is continuously present and may even accumulate;
and no clear re-exposure as the exposure persisted
all the time. Hence, a proper antibody response to
oligomeric A may be hampered by the continuous
presence of the antigen, and might have induced a
form of immune tolerance, as oligomeric A may
have been regarded as “self”. This reasoning would
explain the good response to the cyclic peptides; prior
activation upon a novel antigen in the mouse, subse-
quent absence of this antigen, displaying a proper
response in titer measurements when re-exposed, but
not to A. Moreover, it also may explain the sig-
nificant effects of vaccination in our previous study
[13], in which wild type mice were vaccinated, with
presumably no oligomeric A present, followed by
a period of absence of antigens, and re-exposed to
A in their brains. Absolute antibody titers indeed
appear higher than in the present study (3.5 versus
1.6). That the epitope of the cyclic peptides is shared
with oligomeric A was confirmed by the responses
in mice and human AD tissue [12], in both cases a
first-time presentation. Finally, if presence of even
low levels of oligomeric A in AD patients is hamper-
ing proper antibody responses after vaccination, this
may explain the poor outcome of some of the clinical
studies. In line with this, recent papers indicate that
an effective vaccine should be administered as early
as possible and be as specific as possible, will it stand
a change in the treatment of AD [7, 8, 27, 43]. That
is at least before first appearance of oligomeric A.
Conclusion
J20 mice provide a relevant model to test interfer-
ence with A pathology. The cyclic peptide-based
vaccine, mimicking the oligomeric A structure, did
not evoke a long-lasting antibody response to A,
and accordingly did not reduce plaque load. Never-
theless, vaccination at young ages seemed to prevent
working- and short-term spatial memory loss at later
ages, but deteriorated long-term spatial learning and
memory. Hence cognitive effects cannot be attributed
to altered A pathology. Later vaccination had no
effect within the studied timeframe. Translation of
the message regarding mechanism and timing of vac-
cination into the clinical setting of AD patients will
need further investigation.
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